Valneva (NASDAQ:VALN) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Valneva (NASDAQ:VALN) from a strong sell rating to a sell rating in a research note issued to investors on Saturday.

Other equities research analysts have also issued reports about the company. The Goldman Sachs Group lowered Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target for the company. in a research note on Wednesday, April 22nd. Guggenheim set a $11.00 price target on Valneva in a research note on Thursday, April 16th. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $11.98.

Valneva Stock Performance

NASDAQ VALN opened at $5.68 on Friday. The business’s 50-day moving average price is $7.08 and its 200 day moving average price is $8.59. Valneva has a twelve month low of $5.06 and a twelve month high of $12.25. The company has a market capitalization of $489.10 million, a PE ratio of -3.04 and a beta of 1.72. The company has a current ratio of 2.14, a quick ratio of 1.85 and a debt-to-equity ratio of 2.14.

Valneva (NASDAQ:VALN) last released its earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%.The business had revenue of $35.77 million for the quarter. On average, research analysts predict that Valneva will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Valneva

A number of large investors have recently modified their holdings of the stock. VSM Wealth Advisory LLC grew its stake in shares of Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Valneva in the fourth quarter valued at about $44,000. JPMorgan Chase & Co. acquired a new stake in shares of Valneva in the third quarter valued at about $124,000. XTX Topco Ltd acquired a new stake in shares of Valneva in the fourth quarter valued at about $94,000. Finally, Marex Group plc acquired a new stake in shares of Valneva in the second quarter valued at about $64,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.